Regeneron and Mammoth collaborate on gene editing therapies
The collaboration will combine Regeneron's expertise in AAVs and antibodies with Mammoth's knowledge in compact gene editing to…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
26 Apr 24
The collaboration will combine Regeneron's expertise in AAVs and antibodies with Mammoth's knowledge in compact gene editing to…
26 Apr 24
The biotechnology firm will start its Phase 2a FREE001-TRD-201 clinical trial for FREE001, a ketamine-based combination therapy in…
26 Apr 24
Robotic automation of GenScript’s market-leading cell isolation solution provides an enhanced approach for a time-consuming phase of cell…
26 Apr 24
The partnership will bring together the well-known global range of nutritional health solutions as well as vitamin, minerals,…
26 Apr 24
Revvity, Inc. (NYSE: RVTY) today announced the launch of the Auto-Pure 2400 liquid handler from Allsheng for use with the…
25 Apr 24
Moderna will embed OpenAI’s generative AI tools throughout its organisation and adopt ChatGPT Enterprise to use Generative AI…
25 Apr 24
The sBLA submission is supported by data from Part 1 of RUBY Phase 3 trial which successfully met…
25 Apr 24
The approval was based on results from three controlled clinical trials of females aged 18 and above in…
25 Apr 24
The approval was based on the results from the Phase 3 PROTECT study which reached its primary endpoint…
25 Apr 24
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAseq xHYB Mycobacterium tuberculosis Panel…